Establishment Labs jumps after first patients receive Motiva breast implants

Shares of Establishment Labs are moving higher after the company announced that the first patients in the United States have successfully undergone breast augmentation with Motiva Implants. CEO Juan Jose Chacon-Quiros said in a statement, “With the FDA approval last week, we are experiencing high demand for Motiva Implants – both from surgeons and patients. The FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already talked to more than 400 plastic surgeons post announcement. Since approval, we have already doubled our team to 25 sales reps across the United States, and our story of real innovation, backed by science and data, is resonating strongly. Everything we are seeing suggests that we can be the implant of choice in the United States.” Shares of Establishment Labs are up 13% to $45.88 in midday trading.